News

The FDA approval for Emend is based on two multicenter studies of 1,658 patients undergoing open abdominal surgery. Patients were randomized to receive Emend 40mg one to three

Among the potential therapeutic advantages of this approach is a dramatically increased circulatory half-life of the compound, which could give patients greater exposure to the benefits of any

The agreement sets out how the university and AstraZeneca will work together to identify new ways to treat disease and enhance discovery, preclinical and clinical research in a

Avandamet, a combination of GSK’s Avandia (rosiglitazone maleate) and the diabetes drug metformin, was previously only approved as second-line therapy for patients who were uncontrolled on metformin monotherapy.

The drug is one of two that Takeda has in development as potential successors to its blockbuster hypertension drug Blopress. The other drug vying to take over from

The Scottish Medicines Consortium (SMC) has advised National Health Service (NHS) boards and area drug and therapeutic committees (ADTCs) that Tygacil (tigecycline) is accepted for restricted use within

No statistically significant difference was seen in the primary endpoint or any of the secondary endpoints in the phase IIb clinical trial. The company said that it may

According to a survey of US members of the Association for Research in Vision and Ophthalmology (ARVO), the major prohibitory factor in the use of human eye tissue

MabThera (rituximab) in combination with methotrexate is now indicated for the treatment of adult patients with severe active rheumatoid arthritis (RA) who have had an inadequate response or